Literature DB >> 23404119

MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma.

Xiaoyan Chen1, Dandan He, Xiang Da Dong, Feng Dong, Jiao Wang, Lihua Wang, Jiang Tang, Dan-Ning Hu, Dongsheng Yan, LiLi Tu.   

Abstract

PURPOSE: MicroRNA-124a (miR-124a), an abundant microRNA in the central neuron system, has been linked to tumor progression. Here, we investigated the role of miR-124a in uveal melanoma development.
METHODS: Expression of miR-124a in uveal melanoma cells was examined using real time RT-PCR. The effect of miR-124a on cell proliferation, migration, and invasion was analyzed using MTS assay, flow cytometry, and transwell experiments. The ability of miR-124a to repress tumor growth was tested in vivo. Target genes of miR-124a were first predicted by bioinformatics, confirmed using a luciferase assay, and their expression determined by Western blotting. DNA methylation and histone modification of miR-124a was analyzed by methylation-specific PCR and ChIP assay. Finally, epigenetic drugs were used to alter the expression of miR-124a.
RESULTS: miR-124a expression was downregulated in both uveal melanoma cells and clinical specimens. Transient transfection of miR-124a into uveal melanoma cells inhibited cell growth, migration, and invasion. Moreover, introduction of miR-124a suppressed in vivo growth of tumor. Potential targets of miR-124a were found to include CDK4, CDK6, cyclin D2, and EZH2. Knockdown of EZH2 by siRNA resulted in inhibition of uveal melanoma cell migration and invasion. In addition, miR-124a expression was found to be regulated via epigenetic mechanisms, with its expression restored when cells were treated with a DNA hypomethylating agent, 5-aza-2'-deoxycytidine, and a histone deacetylase inhibitor, trichostatin A.
CONCLUSIONS: Our results demonstrated that miR-124a could function as a potent tumor suppressor by regulation of multiple targets, and was epigenetically silenced in the development of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404119     DOI: 10.1167/iovs.12-10977

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  34 in total

1.  Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.

Authors:  M Ben Dhiab; S Ziadi; F Ksiaa; T Louhichi; R Ben Gacem; A Ben Zineb; K Amara; M Hachana; Mounir Trimeche
Journal:  Tumour Biol       Date:  2014-11-15

Review 2.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

3.  ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma.

Authors:  G M Roberto; L E A Delsin; G M Vieira; M O Silva; R G Hakime; N F Gava; E E Engel; C A Scrideli; L G Tone; María Sol Brassesco
Journal:  Pathol Oncol Res       Date:  2017-12-21       Impact factor: 3.201

Review 4.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

5.  Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.

Authors:  Hongbin Liu; Phillip Pattie; Sahan Chandrasekara; Andrew Spencer; Anthony E Dear
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

Review 6.  Emerging roles of microRNAs and their implications in uveal melanoma.

Authors:  Chun Yang; Yuejiao Wang; Pierre Hardy
Journal:  Cell Mol Life Sci       Date:  2020-08-11       Impact factor: 9.261

7.  MicroRNA-124 Targets Tip110 Expression and Regulates Hematopoiesis.

Authors:  Ying Liu; Xinxin Huang; Khalid Amine Timani; Hal E Broxmeyer; Johnny J He
Journal:  Stem Cells Dev       Date:  2015-05-11       Impact factor: 3.272

8.  Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus.

Authors:  Shu Zhang; Ling-Ji Guo; Gang Zhang; Ling-Li Wang; Shuai Hao; Bo Gao; Yan Jiang; Wu-Guo Tian; Xian-E Cao; Dong-Lin Luo
Journal:  Tumour Biol       Date:  2016-02-20

Review 9.  EZH2 as a mediator of treatment resistance in melanoma.

Authors:  Jessamy C Tiffen; Stuart J Gallagher; Hsin-Yi Tseng; Fabian V Filipp; Barbara Fazekas de St. Groth; Peter Hersey
Journal:  Pigment Cell Melanoma Res       Date:  2016-05-25       Impact factor: 4.693

Review 10.  Non-coding RNAs as direct and indirect modulators of epigenetic regulation.

Authors:  Veronica J Peschansky; Claes Wahlestedt
Journal:  Epigenetics       Date:  2014-01       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.